Methods of treating pain using anti-GPR160 antibodies

Patent metadata

Field	Value
Publication number	US-10851378-B2
Application number	US-201615744540-A
Country	US
Kind code	B2
Filing date	Jul 15, 2016
Priority date	Jul 16, 2015
Publication date	Dec 1, 2020
Grant date	Dec 1, 2020

Abstract

The disclosure provides methods and compositions for inhibiting pain by administering a GPR160 antagonist to a subject in need thereof. Also provided are methods of using GPR160 antagonists in combination with other pain therapies.

First claim

The invention claimed is:

1. A method of treating pain in a subject comprising administering to said subject an amount of a GPR160 antagonist sufficient to treat pain, wherein the GPR160 antagonist is an antibody that specifically binds to GPR160.

2. The method of claim 1 , wherein said subject is a human.

3. The method of claim 1 , wherein said subject is a non-human mammal.

4. The method of claim 1 , wherein said pain is chronic pain.

5. The method of claim 1 , wherein said pain is acute pain.

6. The method of claim 1 , wherein said antagonist is administered with a second anti-pain agent.

7. The method of claim 6 , wherein said antagonist and said second anti-pain agent are co-formulated.

8. The method of claim 6 , wherein said antagonist and said second anti-pain agent are not co-formulated.

9. The method of claim 8 , wherein said antagonist and said second anti-pain agent are delivered at distinct times.

10. The method of claim 9 , wherein said antagonist is delivered before said second anti-pain agent.

11. The method of claim 9 , wherein said antagonist is delivered after said second anti-pain agent.

12. The method of claim 9 , wherein said antagonist and said second anti-pain agent are delivered in alternating administrations.

13. The method of claim 6 , wherein said second anti-pain agent is an opioid or a gabapentanoid.

14. The method of claim 1 , wherein said antagonist is delivered over a period of one week, two weeks, three weeks, four weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, one year, two years or three years.

15. The method of claim 1 , wherein said antagonist is delivered by continuous infusion.

16. The method of claim 15 , wherein continuous infusion is provided by an implanted pump.

17. The method of claim 1 , wherein said pain is the result of an injury.

18. The method of claim 17 , wherein said injury is a penetration wound, a burn, frostbite or a fracture.

19. The method of claim 1 , wherein said pain is the result of a disease.

20. The method of claim 19 , wherein said disease is diabetes, post-surgical pain, cancer, spinal nerve disease, multiple sclerosis, arthritis, an autoimmune disease, or an infection.

21. The method of claim 1 , wherein pain is neuropathic pain.

Assignees

• Univ Saint Louis

Inventors

• Salvemini Daniela
• Yosten Gina L C
• Samson Willis K

Classifications

• C07K14/705 Primary

  Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} · CPC title

• G01N33/566

  using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds} · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C12N15/1138 Primary

  against receptors or cell surface proteins · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title